China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

XSEC:000999 Stock Report

Market Cap: CN¥57.9b

China Resources Sanjiu Medical & Pharmaceutical Valuation

Is 000999 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 000999 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 000999 (CN¥45.11) is trading below our estimate of fair value (CN¥75.01)

Significantly Below Fair Value: 000999 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 000999?

Key metric: As 000999 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 000999. This is calculated by dividing 000999's market cap by their current earnings.
What is 000999's PE Ratio?
PE Ratio17x
EarningsCN¥3.41b
Market CapCN¥57.93b

Price to Earnings Ratio vs Peers

How does 000999's PE Ratio compare to its peers?

The above table shows the PE ratio for 000999 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.3x
600085 Beijing Tongrentang
34.3x15.8%CN¥55.9b
002422 Sichuan Kelun Pharmaceutical
17.5x11.4%CN¥51.9b
000661 Changchun High-Tech Industry (Group)
11.6x19.4%CN¥43.1b
600196 Shanghai Fosun Pharmaceutical (Group)
33.6x30.1%CN¥63.7b
000999 China Resources Sanjiu Medical & Pharmaceutical
17x11.2%CN¥57.9b

Price-To-Earnings vs Peers: 000999 is good value based on its Price-To-Earnings Ratio (17x) compared to the peer average (24.3x).

Price to Earnings Ratio vs Industry

How does 000999's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
000999 17.0xIndustry Avg. 31.8xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 000999 is good value based on its Price-To-Earnings Ratio (17x) compared to the CN Pharmaceuticals industry average (32x).

Price to Earnings Ratio vs Fair Ratio

What is 000999's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

000999 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17x
Fair PE Ratio27.8x

Price-To-Earnings vs Fair Ratio: 000999 is good value based on its Price-To-Earnings Ratio (17x) compared to the estimated Fair Price-To-Earnings Ratio (27.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 000999 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥45.11
CN¥54.20
+20.2%
13.7%CN¥62.00CN¥36.00n/a12
Nov ’25CN¥45.99
CN¥53.95
+17.3%
13.7%CN¥63.00CN¥36.00n/a12
Oct ’25CN¥47.61
CN¥54.95
+15.4%
9.1%CN¥63.00CN¥43.99n/a11
Sep ’25CN¥44.93
CN¥54.64
+21.6%
10.7%CN¥63.27CN¥43.99n/a11
Aug ’25CN¥41.80
CN¥54.00
+29.2%
10.4%CN¥63.27CN¥43.99n/a11
Jul ’25CN¥44.60
CN¥55.23
+23.8%
9.3%CN¥63.27CN¥46.15n/a9
Jun ’25CN¥46.80
CN¥55.18
+17.9%
9.3%CN¥63.27CN¥46.15n/a9
May ’25CN¥46.13
CN¥53.33
+15.6%
11.9%CN¥63.27CN¥42.31n/a9
Apr ’25CN¥40.21
CN¥50.21
+24.9%
12.0%CN¥60.00CN¥42.31n/a9
Mar ’25CN¥41.73
CN¥50.39
+20.8%
13.9%CN¥60.00CN¥39.23n/a9
Feb ’25CN¥41.88
CN¥50.31
+20.1%
13.7%CN¥60.00CN¥39.23n/a9
Jan ’25CN¥38.25
CN¥50.54
+32.1%
14.4%CN¥60.00CN¥39.23n/a8
Dec ’24CN¥37.75
CN¥50.73
+34.4%
14.8%CN¥60.00CN¥39.23n/a8
Nov ’24CN¥33.25
CN¥52.13
+56.8%
15.9%CN¥61.95CN¥39.23CN¥45.998
Oct ’24CN¥38.55
CN¥53.49
+38.7%
12.4%CN¥61.95CN¥45.38CN¥47.618
Sep ’24CN¥36.01
CN¥52.92
+47.0%
11.5%CN¥61.95CN¥45.38CN¥44.938
Aug ’24CN¥38.42
CN¥56.06
+45.9%
9.1%CN¥63.55CN¥46.92CN¥41.809
Jul ’24CN¥46.66
CN¥55.96
+19.9%
9.6%CN¥63.55CN¥46.92CN¥44.608
Jun ’24CN¥49.12
CN¥55.96
+13.9%
9.6%CN¥63.55CN¥46.92CN¥46.808
May ’24CN¥45.35
CN¥52.92
+16.7%
11.3%CN¥63.55CN¥46.92CN¥46.138
Apr ’24CN¥44.19
CN¥51.59
+16.7%
9.6%CN¥63.55CN¥46.92CN¥40.218
Mar ’24CN¥39.92
CN¥49.98
+25.2%
12.0%CN¥63.55CN¥43.46CN¥41.738
Feb ’24CN¥37.20
CN¥48.64
+30.7%
15.5%CN¥63.55CN¥36.15CN¥41.888
Jan ’24CN¥36.01
CN¥45.32
+25.9%
14.0%CN¥54.40CN¥36.15CN¥38.257
Dec ’23CN¥43.28
CN¥43.82
+1.2%
11.8%CN¥50.77CN¥36.15CN¥37.757
Nov ’23CN¥40.12
CN¥43.05
+7.3%
10.3%CN¥48.62CN¥36.15CN¥33.257

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥51.9b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥32.72

7D

7.3%

1Y

15.1%

China Resources Sanjiu Medical & Pharmaceutical

CN¥57.9b

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

999

CN¥45.11

7D

-1.3%

1Y

19.5%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.9b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.32

7D

2.5%

1Y

10.5%